Peter S. Hammerman

30.9k citations

86 papers · 8.1k indexed · 4 hit papers · h-index 42

Impact in

Cancer Research top 0.5%
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers

Papers in

Cancer Research 23
- Cancer Genomics and Diagnostics 14
- Cancer, Hypoxia, and Metabolism 6
Otorhinolaryngology 6

Co-authors: Craig B. Thompson Casey Fox Kwok‐Kin Wong Carla F. Kim Christine M. FillmoreChen ZhaoRyan M. Cinalli David R. Plas
Journals: Cancer Research (14 papers)Journal of Clinical Oncology (7 papers)Clinical Cancer Research (6 papers)Molecular Cancer Therapeutics (5 papers)Blood (5 papers)
Partner nations: United States Switzerland France

In The Last Decade

Peter S. Hammerman

83 papers receiving 8.0k citations

Hit Papers

align trajectories log scale

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma 2017 · 361 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 Immunity
2016 Journal of Clinical Oncology
2014 Nature reviews. Cancer
2005 Nature reviews. Immunology

Peers

Countries citing papers authored by Peter S. Hammerman

Since Specialization

Citations

This map shows the geographic impact of Peter S. Hammerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter S. Hammerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter S. Hammerman more than expected).

Fields of papers citing papers by Peter S. Hammerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter S. Hammerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter S. Hammerman. The network helps show where Peter S. Hammerman may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter S. Hammerman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter S. Hammerman Line = papers co-authored together Peter S. Hammerman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment Cancer Research ·Hui Qin Wang, Iain J. Mulford, Fiona A. Sharp, Jinsheng Liang, Sema Kurtuluş, Gina M. Trabucco, David S. Quinn, Tyler A. Longmire, Nidhi Patel, 大島康次郎, Matthew D. Shirley, Yan Chen, Hao Wang, David A. Ruddy, Claire Fabre, Juliet Williams, Peter S. Hammerman, Jennifer Mataraza, Barbara Platzer, Ensar Halilovic	2021	43
2	SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors Molecular Cancer Therapeutics ·Hengyu Lu, Chen Liu, Roberto Velazquez, Hongyun Wang, E. Chardon, Bahaa Ali Moussa, Yunfei Yan, Éric Billy, Eusebio Manchado, Saskia M. Brachmann, Susan E. Moody, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro, Morvarid Mohseni, Huai‐Xiang Hao	2019	58
3	RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1 -Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade Molecular Cancer Therapeutics ·Bruno Bockorny, Maria Rusan, Wankun Chen, Rachel G. Liao, Yvonne Li, Federica Piccioni, Jun Wang, Li Tan, Aaron R. Thorner, Tianxia Li, Y. Zhang, Changhong Miao, Therese Ovesen, Geoffrey I. Shapiro, David J. Kwiatkowski, Nathanael S. Gray, Matthew Meyerson, Peter S. Hammerman, Adam J. Bass	2018	43
4	NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model Cancer Research ·Yan Liu, Yuyang Li, Shengwu Liu, Dennis O. Adeegbe, Camilla L. Christensen, Max M. Quinn, Ruben Dries, Shiwei Han, Kevin A. Buczkowski, Xiaoen Wang, Ting Chen, Peng Gao, Hua Zhang, Fei Li, Peter S. Hammerman, James E. Bradner, Steven N. Quayle, Kwok‐Kin Wong	2018	40
5	Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma Clinical Cancer Research ·Nicole G. Chau, Yvonne Y. Li, Vickie Y. Jo, Guilherme Rabinowits, Jochen H. Lorch, Roy B. Tishler, Danielle N. Margalit, Jonathan D. Schoenfeld, 胡贝克, Laura A. Goguen, Tom Thomas, Albarino Colunche, 勝弘望月, Jeffrey F. Krane, Neal I. Lindeman, Geoffrey I. Shapiro, Robert I. Haddad, Peter S. Hammerman	2016	39
6	Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6 Cancer Research ·Atish D. Choudhury, Anna C. Schinzel, Maura B. Cotter, Rosina T. Lis, Katherine Labella, T. Kohl, Francesca Izzo, Isil Guney, Michaela Bowden, Yvonne Y. Li, Jinal Patel, Emily C. Hartman, Steven A. Carr, Monica Schenone, Jacob D. Jaffe, Philip W. Kantoff, Peter S. Hammerman, William C. Hahn	2016	30
7	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes Cancer Immunology Research ·Vishwajith Sridharan, Evisa Gjini, Xiaoyun Liao, Nicole G. Chau, Robert I. Haddad, Mariano Severgnini, Peter S. Hammerman, Adel K. El‐Naggar, Gordon J. Freeman, F. Stephen Hodi, Scott J. Rodig, Glenn Dranoff, Jonathan D. Schoenfeld	2016	77
8	Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma Clinical Cancer Research ·Yvonne Y. Li, Glenn J. Hanna, Alvaro C. Laga, Robert I. Haddad, Jochen H. Lorch, Peter S. Hammerman	2015	208
9	NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy Molecular Cancer Therapeutics ·Chunxiao Xu, Kevin A. Buczkowski, Sigurd Laube, Hajime Asahina, Ellen M. Beauchamp, Hideki Terai, Yvonne Y. Li, Matthew Meyerson, Kwok‐Kin Wong, Peter S. Hammerman	2015	24
10	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2 Cancer Research ·Junko Tanizaki, Dalia Ercan, Marzia Capelletti, Michael Dodge, Chunxiao Xu, Magda Bahcall, 里子木村, Mohit Butaney, Antonio Calles, Lynette M. Sholl, Peter S. Hammerman, Geoffrey R. Oxnard, Kwok‐Kin Wong, Pasi A. Jänne	2015	30
11	Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma Clinical Cancer Research ·Marzia Capelletti, Michael Dodge, Dalia Ercan, Peter S. Hammerman, Seung-Il Park, Young Tae Kim, Hidefumi Sasaki, David M. Jablons, Doron Lipson, Lauren Young, Phil Stephens, Vincent A. Miller, Neal I. Lindeman, Kiara J. Munir, William G. Richards, Pasi A. Jänne	2014	79
12	Kinase Domain Activation of FGFR2 Yields High-Grade Lung Adenocarcinoma Sensitive to a Pan-FGFR Inhibitor in a Mouse Model of NSCLC Cancer Research ·Jeremy H. Tchaicha, Esra A. Akbay, Abigail Altabef, Oliver R. Mikse, Eiki Kikuchi, Kevin Rhee, Rachel G. Liao, Roderick T. Bronson, Lynette M. Sholl, Matthew Meyerson, Peter S. Hammerman, Kwok‐Kin Wong	2014	30
13	Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells Oncogene ·Jun Wang, Oliver R. Mikse, Rachel G. Liao, Yi Li, Li Tan, Pasi A. Jänne, Nathanael S. Gray, 杨凌博, Peter S. Hammerman	2014	55
14	Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research ·Mohamed E. Abazeed, Drew Adams, Kristen E. Hurov, Pablo Tamayo, Chad J. Creighton, Dmitriy Sonkin, Andrew O. Giacomelli, Andrew A. Canterbury, Ni Putu Yuliari Nanda Pratiwi, Kwok‐Kin Wong, Jill P. Mesirov, Jay S. Loeffler, Stuart L. Schreiber, Peter S. Hammerman, Matthew Meyerson	2013	90
15	Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss Molecular Cancer Therapeutics ·Ellen M. Beauchamp, Brittany A. Woods, Austin Dulak, Li Tan, Chunxiao Xu, Nathanael S. Gray, Adam J. Bass, Kwok‐Kin Wong, Matthew Meyerson, Peter S. Hammerman	2013	44
16	Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma Cancer Research ·Rachel G. Liao, Joonil Jung, Jeremy H. Tchaicha, Matthew D. Wilkerson, Andrey Sivachenko, Ellen M. Beauchamp, Qingsong Liu, Trevor J. Pugh, Chandra Sekhar Pedamallu, D. Neil Hayes, Nathanael S. Gray, Gad Getz, Kwok‐Kin Wong, Robert I. Haddad, Matthew Meyerson, Peter S. Hammerman	2013	134
17	Multiple signaling pathways promote B lymphocyte stimulator–dependent B-cell growth and survival Blood ·Robert T. Woodland, Casey Fox, Madelyn R. Schmidt, Peter S. Hammerman, Joseph T. Opferman, Stanley J. Korsmeyer, David M. Hilbert, Craig B. Thompson	2007	152
18	The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor Genes & Development ·Casey Fox, Peter S. Hammerman, Ryan M. Cinalli, Stephen R. Master, Lewis A. Chodosh, Craig B. Thompson	2003	271
19	Akt-Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote Growth Factor-Independent Survival Molecular and Cellular Biology ·Jeffrey C. Rathmell, Casey Fox, David R. Plas, Peter S. Hammerman, Ryan M. Cinalli, Craig B. Thompson	2003	478
20	In Search of a Gene for Hereditary Cholestasis Biochemical and Molecular Medicine ·Melissa Ancheta, Laura N. Bull, Noureddine Lomri, Bill Dahl, Thomas Luther, Peter S. Hammerman, 恒雄長谷川, Nelson B. Freimer, Bruce F. Scharschmidt	1996	5

About Peter S. Hammerman

Peter S. Hammerman is a scholar working on Cancer Research, Otorhinolaryngology, Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 86 papers that have together received 8.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (25 papers), Cancer Genomics and Diagnostics (14 papers), RNA modifications and cancer (14 papers), Fibroblast Growth Factor Research (13 papers), Cancer Immunotherapy and Biomarkers (12 papers), Epigenetics and DNA Methylation (9 papers), Lung Cancer Research Studies (8 papers) and Cancer, Hypoxia, and Metabolism (6 papers). The work is most often cited by research in Cancer Research (2.1k citations), Oncology (3.0k citations), Immunology (1.5k citations), Pulmonary and Respiratory Medicine (2.1k citations) and Molecular Biology (4.3k citations). Peter S. Hammerman has collaborated with scholars based in United States, Switzerland and France. Frequent co-authors include Craig B. Thompson, Casey Fox, Kwok‐Kin Wong, Carla F. Kim, Christine M. Fillmore, Chen Zhao, Ryan M. Cinalli, David R. Plas, Yvonne Y. Li and Jeffrey C. Rathmell. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Clinical Cancer Research, Molecular Cancer Therapeutics and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact